This inventor holds 1 USPTO granted patent. Top assignee: Pure Tech Lyt 100, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: David Andrew Golod: Innovator in Pulmonary Fibrosis Treatment
Introduction
David Andrew Golod is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of medicine, particularly in the treatment of idiopathic pulmonary fibrosis (IPF). His innovative approach has the potential to improve the lives of many patients suffering from this challenging condition.
Latest Patents
Golod holds a patent for "Methods of treating idiopathic pulmonary fibrosis with deupirfenidone." This patent discloses a method that includes administering deuterium-enriched pirfenidone, known as LYT-100, at a total daily dose ranging from about 1650 mg to about 2500 mg. This advancement represents a promising step forward in the management of IPF.
Career Highlights
David Andrew Golod is associated with PureTech Lyt 100, Inc., where he continues to work on innovative solutions for pulmonary diseases. His dedication to research and development has positioned him as a key figure in the medical community.
Collaborations
Golod collaborates with esteemed colleagues, including Michael C. Chen and Eric Elenko. Their combined expertise fosters a dynamic environment for innovation and progress in the treatment of pulmonary conditions.
Conclusion
David Andrew Golod's contributions to the treatment of idiopathic pulmonary fibrosis highlight his role as an influential inventor in the medical field. His work not only advances scientific knowledge but also offers hope to patients in need of effective therapies.